Hanmi Pharm. Co., Ltd.

Hanmi Science Co., Ltd.

Sanofi-a Ventis Deutschland Gmbh

Dongbu Hitek Co., Ltd.

Korea Research Institute of Chemical Technology

Beijing Hanmi Pharmaceutical Co., Ltd.

Hanmi Holdings Co., Ltd.

Dongbu Farm Hannong Co., Ltd.

In Young Choi

Jin Young Kim

Sung Youb Jung

Se Chang Kwon

Sung Hee Park

Young Jin Park

Jong Soo Lee

Dae Jin Kim

Jung Kuk Kim

Young Eun Woo

Chang Hwan Kim

Gwan Sun Lee

Seung Su Kim

Sang Hyun Lee

Young Min Kim

Dae Hae Song

Myung Hyun Jang

Hyung Kyu Lim

Euh Lim Oh

Young Hoon Kim

Jae Ho Lee

Jong Min Lee

Tae Joon Kim

Jaehyuk Choi

Norbert Tennagels

Sung Hwan Moon

Jae Wook Ryu

Hyun Uk Kim

Chang Ki Lim

Stefan Guessregen

Min Young Kim

Young Kwan Ko

Jiawang Liu

Hyun Ji Lee

Dong Wan Koo

Jae Chun Woo

Jong Suk Lee

Sang Youn Hwang

Yong Ho Huh

Jun Hyuk Choi

Jin-Sun Kim

Kyoung Sung Kim

Sung Hee Hong

Dae Whang Kim

Mi Ji Lee

Seong Hee Park

Ling Ai Shen

Byung Sun Lee

Marcus Korn

Yong Ho Heo

Kun Hoe Chung

Tae Hyun Oh

Hyo Sang Jo

Se Young Lim

Sung Kap Hong

Tae Hun Song

Eui Joon Jung

Kyung Sung Kim

Gi Jun Moon

Bong Jin Chung

Mi Sook Hong

Soo Young Kwak

Young Kwon Kim

Mee Young Seok

Dac Hae Song

Hyun Joo Kwon

Ryoung Ae Shin

Eun Jin Park

Hee Chul Kang

A fusion protein of a dimeric therapeutic enzyme and an immunoglobulin Fc region, a preparation method thereof, and a composition containing the fusion protein are disclosed.

Therapeutic enzyme fusion protein having a novel structure and use thereof

The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.

Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof

The present invention relates to an insulin analog conjugate and use thereof.

Insulin analog complex with reduced affinity for insulin receptor and use thereof

A glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof are disclosed.

Glucagon derivative and a composition comprising a long acting conjugate of the same

A glucagon-like peptide-2 (GLP-2) derivative, a conjugate thereof, and a use thereof are disclosed. Additionally, a method for preparing a glucagon-like peptide-2 (GLP-2) derivative and a conjugate thereof is disclosed.

Long-acting conjugates of GLP-2 derivatives

The present invention relates to a novel insulin analog, use thereof, and a method for preparing the analog.

Insulin analogs with reduced affinity to insulin receptor and use thereof

A modified IgG4 Fc fragment useful as a drug carrier is disclosed. When coupled to a drug, the resulting drug-IgG4 Fc conjugate can minimize the effector functions of the IgG4 Fc and the chain exchange with in vivo IgG while maintaining in vivo activity and improving in vivo duration of the drug conjugate.

IgG4 Fc fragment comprising modified hinge region

The present invention relates to a glucagon derivative, a conjugate thereof, and a composition comprising the same, and a therapeutic use thereof, and in particular, for metabolic syndrome, hypoglycemia, and congenital hyperinsulinism.

Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof

The present invention relates to a modified IgG4 Fc fragment useful as a drug carrier. When the modified IgG4 Fc fragment of the present invention is combined with an arbitrary drug, the resulting drug conjugate can minimize the effector functions of the IgG4 Fc and the chain exchange with in vivo IgG while maintaining in vivo activity and improving in vivo duration of the drug conjugate.

The present invention relates to a glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof.

An insulin analog with an improved in vitro effect compared with native insulin, a pharmaceutical composition for treating diabetes containing the insulin analog as an active ingredient, and a method for treating diabetes using the insulin analog or the pharmaceutical composition are described. A nucleic acid encoding the insulin analog, an expression vector including the nucleic acid, a transformant introduced with the expression vector, and a method of producing the insulin analog from the transformant are also described.

Insulin analogs and use thereof

The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. The oxyntomodulin derivative has a high ability to activate GLP-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol/low-density cholesterol ratio. Thus, the oxyntomodulin derivative can be effectively used for the treatment of hyperlipidemia and related diseases.

Composition for treating hyperlipidemia comprising oxyntomodulin derivative

The present invention relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease including a long-acting GLP-1/glucagon receptor dual agonist, and a method for preventing or treatment of non-alcoholic fatty liver disease including administering the composition. The composition of the present invention either has no side effect of weight gain or reduces the side effect of weight gain, which is a side-effect of conventional therapeutic agents for non-alcoholic fatty liver disease, and reduces the amount of administrations of a long-acting GLP-1/glucagon receptor dual agonist, thus greatly improving patient's convenience. In addition, the long-acting GLP-1/glucagon receptor dual agonist of the present invention improves in vivo sustainability and stability.

Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease

Growing community of inventors

Yongin-si, South Korea

In Young Choi